TGF-β相关遗传评分定义晚期上皮性卵巢癌预后与铂类敏感性
研究纳入230例接受铂类化疗的晚期上皮性卵巢癌患者,分析34个免疫相关基因上192个单核苷酸多态性。构建基于7个TGF-β通路不利基因型的遗传评分,随不利基因型数量增加,总生存期、无进展生存期和铂类无治疗间期均下降,p<0.0001。
要点
- 基于7个TGF-β通路不利基因型的评分与晚期上皮性卵巢癌预后相关。
- 不利基因型0-2、3-4、5-7组中位总生存期分别为未达到、44.6和19.3个月。
- 中位无进展生存期分别为21.5、17.3和11个月,铂类无治疗间期分别为16.6、9.8和3.8个月。
核心结论
- 所提出的TGF-β通路评分可能有助于定义晚期上皮性卵巢癌患者的预后和铂类敏感性。
研究设计与样本
- 研究纳入230例接受铂类化疗的晚期上皮性卵巢癌患者,采用Illumina GoldenGate基因分型芯片分析生殖系DNA中34个免疫相关基因上的192个单核苷酸多态性。
主要发现
- 19个多态性与总生存期显著相关,17个与无进展生存期相关,20个与铂类无治疗间期相关。
- 与全部三项结局相关的8个多态性中,7个属于TGF-β通路相关基因。
- 按7个多态性的不利基因型数量分组,中位总生存期在0-2、3-4、5-7个不利基因型组分别为未达到、44.6和19.3个月,p<0.0001。
- 中位无进展生存期在0-2、3-4、5-7个不利基因型组分别为21.5、17.3和11个月,p<0.0001。
- 中位铂类无治疗间期在0-2、3-4、5-7个不利基因型组分别为16.6、9.8和3.8个月,p<0.0001。
关键数值与推荐
- 遗传评分分组:0-2个不利基因型、3-4个不利基因型、5-7个不利基因型。
临床怎么用
- 原文结论认为该TGF-β通路评分可能有助于定义晚期上皮性卵巢癌患者的预后和铂类敏感性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Epithelial ovarian cancer (EOC) is usually diagnosed at advanced stages with highly variable clinical outcomes, even among patients with similar clinical characteristics and treatments. Host immune system plays a pivotal role in EOC pathogenesis and progression. Here, we assessed the clinical significance of 192 single nucleotide polymorphisms (SNPs) on 34 immune-system related genes in EOC patients. METHODS: Two hundred and thirty advanced EOC patients treated with platinum-based chemotherapy were included. Germ-line DNA was analyzed with Illumina GoldenGate Genotyping Assay. RESULTS: Nineteen polymorphisms were significantly associated with overall survival (OS), 17 with progression free survival (PFS) and 20 with platinum-free interval (PFI). Of the 8 polymorphisms associated with all three outcomes, 7 SNPs belonged to genes involved in the TGF-β pathway. A genetic score was built considering the unfavourable genotypes (UGs) of these 7 polymorphisms (group 0-2 UGs: presence of 0, 1, or 2 UGs; group 3-4 UGs: 3 or 4 UGs; group 5-7: 5, 6, or 7 UGs). According to this score, OS decreased as the number of UGs increased (median OS: 0-2 UGs = not reached, 3-4 UGs = 44.6 and 5-7 UGs = 19.3 months, p < 0.0001). The same trend was observed also for PFS (median PFS: 0-2 UGs = 21.5, 3-4 UGs = 17.3 and 5-7 UGs = 11 months, p < 0.0001) and PFI (median PFI: 0-2 UGs = 16.6, 3-4 UGs = 9.8 and 5-7 UGs = 3.8 months, p < 0.0001). The score was validated by permutation analysis. CONCLUSIONS: The proposed TGF-β pathway score could be useful to define prognosis and platinum sensitivity of advanced EOC patients.
引用
- Gagno S, Poletto E, Bartoletti M, et al. A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer. Gynecol Oncol. 2019. PMID: 31711657. doi:10.1016/j.ygyno.2019.10.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。